Dulaglutide Dosage, half-life & reference guide
Also known as Trulicity · LY2189265 · Dula
A weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens. Its effect on weight is modest, about 1 to 5 kg on average in its diabetes trials depending on the dose, and it is not approved for weight loss.
- FDA label
- 0.75–4.5 mgstarting dose 0.75 mg
- How often
- Weekly
- Half-life
- ~5 days
- Evidence
- ●●●
Established - Route
- SubQ injection
How it works.
GLP-1 receptor agonist made as a fusion protein: two GLP-1 analogue chains, 90% the same as human GLP-1, joined to the Fc fragment of a modified IgG4 antibody (about 63 kDa). It releases insulin when glucose is high, lowers glucagon and slows stomach emptying. Its large Fc-fusion design slows its clearance, to a half-life of about 5 days, which makes it a weekly shot. FDA-approved in 2014 for type 2 diabetes (adults, and children 10 and older) and to lower major cardiovascular events in adults with type 2 diabetes and heart disease or its risk factors; it is not approved for weight management.
Commonly reported: Steadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it.
Half-life & active level
The half-life of Dulaglutide is ~5 days (FDA label).
Here's how a typical Dulaglutide schedule accumulates over four weeks (one-compartment estimate).
An estimate from the half-life above, not a measurement. See your own curve build live in the half-life calculator.
Week by week.
What to expect in the first 8 weeks
- Onset
- Days–2 weeks
- Peak effect
- 24–52 weeks (glucose)
- Duration
- Ongoing
Day 1–28 · 0.75 mgRCT
The 0.75 mg start
You're on 0.75 mg, the label's starting dose, which already lowers blood sugar. Commonly reported: a little nausea, loose stools or less appetite in the days after the shot, easing over the first weeks.
The science
The Trulicity label (effective June 2026) starts adults at 0.75 mg weekly and allows 1.5 mg after 4 weeks, stepping up to limit GI side effects. In the pooled placebo-controlled trials, nausea affected 12.4% on 0.75 mg vs 5.3% on placebo. The slowing of stomach emptying is largest after the first dose and fades with later doses.
Sources- FDA Trulicity label (2026)
Updated Oct 2026
Day 29–364 · 1.5 mgRCT
1.5 mg, the dose of its heart trial
At 1.5 mg, the dose REWIND tested for over five years, glucose control steadies, and for some appetite runs a little lower. Commonly reported: nausea for a day or two after the step-up, then settling.
The science
REWIND (Gerstein 2019) randomized 9,901 adults with type 2 diabetes and heart disease or its risk factors to dulaglutide 1.5 mg or placebo for a median of 5.4 years: major cardiovascular events occurred in 12.0% vs 13.4% (HR 0.88). In the pooled placebo-controlled trials, decreased appetite was reported by 8.6% on 1.5 mg vs 1.6% on placebo (label).
Sources- Gerstein et al. (REWIND) (2019)
- FDA Trulicity label (2026)
Updated Oct 2026
Any dayRCT
What Dulaglutide is built on
More than a decade of use: FDA approval in 2014, the AWARD trial program, the five-year REWIND heart trial and a high-dose trial of 3 and 4.5 mg. It is approved for type 2 diabetes, not for weight loss.
The science
Eli Lilly's Trulicity is a GLP-1 analogue fused to a modified IgG4 Fc fragment (label). REWIND (Gerstein 2019, 9,901 adults) supports its cardiovascular indication and AWARD-11 (Frias 2021, 1,842 adults) its 3 and 4.5 mg doses. In the head-to-head SUSTAIN 7 (Pratley 2018), semaglutide 1 mg lowered HbA1c (1.8 vs 1.4 points) and weight (6.5 vs 3.0 kg) more than dulaglutide 1.5 mg at 40 weeks.
Sources- Gerstein et al. (REWIND) (2019)
- Frias et al. (AWARD-11) (2021)
- Pratley et al. (SUSTAIN 7) (2018)
Updated Oct 2026
With BPC-157Community
Why people add BPC-157 to a GLP-1
Some people add BPC-157, first studied as a stomach-protecting peptide, hoping it eases GLP-1 stomach upset. Commonly reported: smoother step-ups; no trial has tested it with dulaglutide.
The science
BPC-157 is a fragment of a body protection compound first isolated from human gastric juice, and its gut research is almost all in animals (Sikiric 2018). No trial has tested the pairing; the pattern comes from community reports.
Sources- Sikiric et al. (2018)
Updated Oct 2026
After week 8
Day 57–364 · 3 mgRCT
3 mg, a step for more glucose control
3 mg is the label's first optional step past 1.5 mg, for people who need more glucose control. In its trial it lowered weight a little more than 1.5 mg, with nausea close to the 1.5 mg rate.
The science
AWARD-11 (Frias 2021) randomized 1,842 adults on metformin to 1.5, 3 or 4.5 mg; everyone started at 0.75 mg and stepped up every 4 weeks. At 36 weeks, 3 mg lowered weight by 3.8 kg vs 3.0 kg on 1.5 mg and HbA1c by 1.6 vs 1.5 points (label table); its HbA1c edge over 1.5 mg was significant on the efficacy estimand only. Nausea: 15.6% on 3 mg vs 13.4% on 1.5 mg.
Sources- Frias et al. (AWARD-11) (2021)
- FDA Trulicity label (2026)
Updated Oct 2026
Day 85–364 · 4.5 mgRCT
4.5 mg, the top dose
4.5 mg is the label's maximum. In its 36-week trial it lowered HbA1c by 1.8 points and weight by 4.6 kg on average, against 1.5 points and 3.0 kg on 1.5 mg.
The science
AWARD-11 (Frias 2021): 4.5 mg beat 1.5 mg for HbA1c and weight on both estimands (treatment-regimen HbA1c −1.77 vs −1.54 points; weight −4.6 vs −3.0 kg). Vomiting affected 9.3% on 4.5 mg vs 5.6% on 1.5 mg through 36 weeks. 4.5 mg is an adult dose; the pediatric label stops at 1.5 mg.
Sources- Frias et al. (AWARD-11) (2021)
- FDA Trulicity label (2026)
Updated Oct 2026
Day 365+RCT
A long-term medicine, not a course
Dulaglutide is studied as an ongoing treatment: its heart trial followed people for a median of 5.4 years. Staying on it, changing the dose or stopping is a call for you and your clinician.
The science
In REWIND (Gerstein 2019), the cardiovascular result (HR 0.88 for major cardiovascular events) came from a median 5.4 years of continued 1.5 mg dosing; all-cause death was 10.8% vs 12.0% (HR 0.90, not statistically significant). Gastrointestinal events were reported by 47.4% on dulaglutide vs 34.1% on placebo over the trial.
Sources- Gerstein et al. (REWIND) (2019)
Updated Oct 2026
Day 1 is the day you start it.
FDA Trulicity label (DailyMed, effective June 2026); AWARD-11 (Frias 2021); REWIND (Gerstein 2019); SUSTAIN 7 (Pratley 2018). Approved for type 2 diabetes, not weight management.
Clinical trial data
A typical run.
Run notes
- Cycle
- FDA-approved for ongoing use; its heart-outcomes trial followed people for a median of 5.4 years. The 3 and 4.5 mg steps are optional, for more glucose control.Community practice — opinions vary. Not a clinical recommendation.
- Timing
- Once weekly, any time of day, with or without food, in the abdomen, thigh or upper arm (label). Per the label, a missed dose is given if at least 3 days remain before the next one, and skipped otherwise. Drug levels reach a steady state over 2 to 4 weekly doses.
- Route
- SubQ injection
- Stacks
- BPC-157 (GI support)
Safety.
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
- Indigestion
- Fatigue
Interactions
Dulaglutide slows stomach emptying, most after the first dose, which can slow the absorption of oral medicines: at 1.5 mg it did not change the absorption of the oral drugs tested to a clinically relevant degree, there is little data at 3 and 4.5 mg, and the label suggests monitoring narrow-margin drugs such as warfarin. With insulin or a sulfonylurea, the label suggests considering lower doses of those to limit low blood sugar. It is a GLP-1 drug itself, so it is not stacked with another one. Discuss all your medicines with your clinician.
Safety notes
The Trulicity label carries the GLP-1 class boxed warning: dulaglutide caused thyroid C-cell tumors in rats given it for a lifetime, and whether it does so in people is not known, so the label rules it out for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Its other warnings are acute pancreatitis (confirmed in 0.2% on 1.5 mg, 0.3% on 3 mg and 0.5% on 4.5 mg in the high-dose trial), low blood sugar when combined with insulin or a sulfonylurea, serious allergic reactions, kidney injury from dehydration after vomiting or diarrhea, severe stomach problems, a temporary worsening of diabetic retinopathy when glucose improves quickly, gallbladder disease, and food reaching the lungs under anesthesia. In the placebo-controlled trials, GI side effects affected 32% on 0.75 mg and 41% on 1.5 mg vs 21% on placebo, mostly mild or moderate, and resting heart rate rose 2 to 4 beats per minute on average. These are label findings; review them with your clinician.
Goes with.
Questions people ask.
What is Dulaglutide?
A weekly GLP-1 pen (Trulicity) for type 2 diabetes: it lowers blood sugar and, in people at cardiovascular risk, the combined risk of heart attack, stroke and cardiovascular death, and it comes in four ready-dosed pens. Its effect on weight is modest, about 1 to 5 kg on average in its diabetes trials depending on the dose, and it is not approved for weight loss.
How is Dulaglutide dosed in research?
The FDA label range for Dulaglutide is 0.75–4.5 mg, weekly, with a 0.75 mg starting dose.
How long does Dulaglutide last?
The half-life of Dulaglutide is ~5 days (FDA label).
What do people report on Dulaglutide?
Commonly reported on Dulaglutide: steadier glucose readings and, for some, a smaller appetite, with nausea or loose stools mostly in the first weeks and after a step-up. FDA-approved since 2014, with more than a decade of use behind it.
Is Dulaglutide safe?
The research basis for Dulaglutide is established: clinical trials or FDA-approved use exists. Common side effects in the library: nausea, diarrhea, vomiting, abdominal pain, decreased appetite, indigestion and fatigue.
What does Dulaglutide stack with?
Common stacks for Dulaglutide: BPC-157 (GI support).
Research.
Reference.
- Cadence
Weekly
- Half-life
~5 days
~5 days (FDA label)
- Research basis
●●●
EstablishedClinical trials or FDA-approved use exists
PepVault for iPhone
Track Dulaglutide in PepVault
Log every dose and watch its estimated active level. 7 days free on the yearly plan for new subscribers.
Reviewed How we check the library